Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children.
J Pediatr Hematol Oncol
; 41(1): 38-41, 2019 01.
Article
em En
| MEDLINE
| ID: mdl-30080752
ABSTRACT
The delay in platelet recovery after hematopoietic stem cell transplantation (HSCT) is closely related to the overall survival rate of transplanted children. The use of platelet-producing agents such as eltrombopag and romiplostim has made great progress in treating diseases such as immune thrombocytopenia and aplastic anemia. However, the use of such drugs in patients with thrombocytopenia after transplantation, especially in children, is rare. This study aimed to report eltrombopag treatment for 3 children with primary platelet engraftment failure and secondary thrombocytopenia after allogeneic HSCT. Of these patients, 2 had platelets stabilized at ≥50×10/L after eltrombopag treatment and subsequent withdrawal of eltrombopag. All 3 patients showed no clear adverse reactions. The results indicated a wide application prospect of eltrombopag treatment in children with thrombocytopenia after allogeneic HSCT.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pirazóis
/
Trombocitopenia
/
Benzoatos
/
Transplante de Células-Tronco Hematopoéticas
/
Recuperação de Função Fisiológica
/
Hidrazinas
Tipo de estudo:
Etiology_studies
Limite:
Adolescent
/
Child
/
Humans
/
Male
Idioma:
En
Revista:
J Pediatr Hematol Oncol
Assunto da revista:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
China